TAK-360

DRUG7 trials

Sponsors

Takeda Development Center Americas Inc., Takeda

Conditions

Idiopathic HypersomniaIdiopathic Hypersomnia (IH)Narcolepsy Type 1Narcolepsy Type 2Narcolepsy with Cataplexy (NT1)Narcolepsy without Cataplexy (NT2)

Phase 2

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

RecruitingNCT06812078

TakedaIdiopathic Hypersomnia

Start: 2025-02-07End: 2026-11-30Target: 96Updated: 2026-07-15

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

RecruitingNCT06952699

TakedaNarcolepsy Type 2

Start: 2025-05-06End: 2026-11-30Target: 88Updated: 2026-08-20

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)

RecruitingCTIS2024-517712-29-00

Takeda Development Center Americas Inc.Idiopathic Hypersomnia (IH)

Start: 2025-05-27Target: 48Updated: 2026-01-08

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)

RecruitingCTIS2024-517711-70-01

Takeda Development Center Americas Inc.Narcolepsy without Cataplexy (NT2)

Start: 2025-12-04Target: 12Updated: 2025-11-21

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

RecruitingNCT07633301

TakedaNarcolepsy Type 1

Start: 2026-06-04End: 2027-11-28Target: 92Updated: 2026-06-29

A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia

RecruitingNCT07646678

TakedaIdiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2

Start: 2026-06-11End: 2031-06-15Target: 500Updated: 2026-09-18

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Not yet recruitingCTIS2025-522587-33-00

Takeda Development Center Americas Inc.Narcolepsy with Cataplexy (NT1)

Target: 22Updated: 2026-06-22